Literature DB >> 9557820

Chronic treatment of female rhesus monkeys with low doses of the antiprogestin ZK 137 316: establishment of a regimen that permits normal menstrual cyclicity.

M B Zelinski-Wooten1, O D Slayden, K Chwalisz, D L Hess, R M Brenner, R L Stouffer.   

Abstract

Large doses of antiprogestin typically disrupt menstrual cyclicity. A chronic low-dose regimen of the potent new antiprogestin ZK 137 316, which permits continued menstrual cyclicity but alters gonadal-reproductive tract activity, was established. Rhesus monkeys received vehicle (n = 6) or 0.01 (n = 8), 0.03 (n = 8) or 0.1 (n = 5) mg ZK 137 316/kg body weight daily for five menstrual cycles (C-1 to C-5). Oestradiol, progesterone and gonadotrophin profiles were normal during cycles involving vehicle and 0.01 and 0.03 mg ZK 137 316/kg body weight. In the 0.1 mg/kg group, mid-cycle oestradiol and gonadotrophin surges, and subsequent progesterone production, were absent in C-3 and C-5. Ovarian cyclicity was accompanied by timely menstruation in the vehicle and 0.01 mg/kg groups. By C-3, half the animals in the 0.03 mg/kg group and all animals in the 0.1 mg/kg group were amenorrhoeic. A corpus luteum was noted during the mid-luteal phase of C-5 in the vehicle, 0.01 mg/kg and 0.03 mg/kg groups. Large antral and cystic follicles were evident in the 0.1 mg/kg group. Thus, a daily treatment with 0.01 mg/kg ZK 136317 permitted normal menstrual cyclicity in macaques. While the daily administration of 0.03 mg/kg ZK 136 317 allowed ovarian cyclicity, menstruation was disrupted in some animals. Increasing the dose to 0.1 mg/kg antagonized pituitary function and resulted in anovulation and amenorrhoea. A chronic low-dose regimen of the antiprogestin ZK 137 316, which permits normal ovarian/menstrual cyclicity, has potential as a contraceptive in women.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9557820     DOI: 10.1093/humrep/13.2.259

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  6 in total

1.  Injection of antiangiogenic agents into the macaque preovulatory follicle: disruption of corpus luteum development and function.

Authors:  Timothy M Hazzard; Richard M Rohan; Theodore A Molskness; John W Fanton; Robert J D'Amato; Richard L Stouffer
Journal:  Endocrine       Date:  2002-04       Impact factor: 3.633

2.  Ovarian surface epitheliectomy in the non-human primate: continued cyclic ovarian function and limited epithelial replacement.

Authors:  Jay W Wright; Tanja Pejovic; Leigh Jurevic; Cecily V Bishop; Theodore Hobbs; Richard L Stouffer
Journal:  Hum Reprod       Date:  2011-03-18       Impact factor: 6.918

3.  Dynamic changes in gene expression that occur during the period of spontaneous functional regression in the rhesus macaque corpus luteum.

Authors:  Randy L Bogan; Melinda J Murphy; Jon D Hennebold
Journal:  Endocrinology       Date:  2008-10-23       Impact factor: 4.736

Review 4.  Physiological Action of Progesterone in the Nonhuman Primate Oviduct.

Authors:  Ov D Slayden; Fangzhou Luo; Cecily V Bishop
Journal:  Cells       Date:  2022-05-03       Impact factor: 7.666

5.  Evaluation of the phosphodiesterase 3 inhibitor ORG 9935 as a contraceptive in female macaques: initial trials.

Authors:  Jeffrey T Jensen; Richard L Stouffer; Jessica E Stanley; Mary B Zelinski
Journal:  Contraception       Date:  2009-11-06       Impact factor: 3.375

Review 6.  Animal models of contraception: utility and limitations.

Authors:  Emma R Liechty; Ingrid L Bergin; Jason D Bell
Journal:  Open Access J Contracept       Date:  2015-04-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.